Finasteride for Health & Longevity

Created on 11/06/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Finasteride is an inexpensive prescription oral medication used for an enlarged prostate and pattern hair loss. Its clearest benefits are fewer complications from an enlarged prostate and slower hair loss, plus fewer prostate cancer diagnoses, mostly of slow-growing tumors. Whether it lengthens life is unproven. Sexual side effects affect a minority of users; mood effects and symptoms persisting after stopping are contested. Benefits fade once the drug is stopped. (Full Review)

Protocol

Prostate enlargement
5 mg once daily
Alone or with doxazosin; retention and surgery benefits accrue over years
Male pattern hair loss
1 mg once daily
Often paired with topical minoxidil; any consistent time, with or without meals
Prostate cancer risk reduction (off-label)
5 mg daily for 7 years
Prevention-trial regimen in men 55 or older with PSA ≤3.0 ng/mL; not approved for this use
Time to effect
Prostate enlargement
Over 1 year
Symptom benefit mainly in trials longer than one year
Male pattern hair loss
3 or more months
Of daily use; gains reverse within 12 months of stopping
Less prostate-related bleeding
2–4 weeks
Of 5 mg; less blood loss during prostate surgery

Benefits

Contraindications
  • Women who are or may become pregnant
  • Children and adolescents
  • Hypersensitivity to finasteride or tablet components
  • Men with current depression or suicidal thoughts (inferred)
  • Men seeking conception soon with poor baseline semen quality (inferred)
Key Interactions
  • Doxazosin: additive urinary benefit, plus doxazosin's dizziness on standing
  • Terazosin: inconsistent rise in finasteride exposure; clinical significance undetermined
  • Testosterone (testosterone enanthate): lower prostate and PSA response
  • Oral testosterone: higher testosterone levels with some oral forms
  • NSAIDs (ibuprofen): long co-use linked to higher persistent erectile dysfunction risk
  • Glucocorticoids (e.g., prednisolone): stronger glucocorticoid metabolic effects
  • PSA blood test: lowered by about 50%
  • Tadalafil: partial offset of finasteride's sexual effects
  • St John's wort: possibly weaker hair or prostate response
  • Topical minoxidil: additive hair benefit
Theoretical (inferred from mechanism)
  • Other 5α-reductase inhibitors (dutasteride): additive DHT suppression and sexual side effects
  • Strong CYP3A4 inhibitors (ketoconazole tablets, grapefruit juice): possibly more DHT-related side effects
  • Strong CYP3A4 inducers (rifampin): weaker hair or prostate response
  • Saw palmetto, beta-sitosterol, pumpkin seed oil: additive DHT lowering and overlapping sexual effects
  • SSRIs (e.g., sertraline) and spironolactone: additive sexual dysfunction and harder attribution of mood changes

Risk & Side Effects

  • High: Sexual dysfunction during use
  • Medium: High-grade prostate cancer; gynecomastia; reduced ejaculate volume and semen quality; depression, self-harm and suicidal ideation; floppy iris during cataract surgery
  • Low: Persistent symptoms after stopping; new-onset type 2 diabetes; dementia diagnosis; masked PSA and delayed cancer detection; hypersensitivity reactions and testicular pain; genital malformation in an exposed male fetus
  • Speculative:

Monitoring

Marker Target Why
PSA 0–4.0 ng/mL; on finasteride, track change from the lowest on-treatment value Safety check: a confirmed rise prompts evaluation
Serum DHT Roughly 30–85 ng/dL in men, varying by assay; track percentage suppression from own baseline Confirms drug effect
Total testosterone Roughly 264–916 ng/dL in men Expected to rise about 15%
HbA1c 4.0–5.6% Safety check: diabetes signal
IIEF-5 score No established target; track change from own baseline Safety check: a sustained fall prompts dose review
PHQ-9 score No established target; track change from own baseline Safety check: new depression or suicidal thoughts stop 1 mg use
IPSS (prostate users) No established target; track change from own baseline Expected to change: improvement
Semen analysis (if planning conception) Sperm concentration ≥16 million/mL Safety check: reduced quality prompts pausing

Cadence: Baseline before the first dose; then 3 months, 6 months, then every 12 months: questionnaires at each visit, PSA re-baselined at 6 months and then checked annually, HbA1c annually; hair photographs at 6 and 12 months

Qualitative Assessment

  • Hair shedding and density on standardized photographs
  • Libido, erection quality and ejaculate volume
  • Mood, motivation and emotional flatness
  • Sleep quality and mental clarity
  • Urinary stream and nighttime urination (prostate users)
  • Breast tenderness or enlargement